CTSO - シトソ―ベンツ (Cytosorbents Corporation) シトソ―ベンツ



symbol CTSO
会社名 Cytosorbents Corp (シトソ―ベンツ)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical/Dental Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product CytoSorb which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation organ failure and death in common critical illnesses such as sepsis burn injury trauma lung injury and pancreatitis. In addition CytoSorb is used in other inflammatory conditions such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology including HemoDefend ContrastSorb DrugSorb BetaSorb and others.   シトソ―ベンツは、免疫療法に特化した米国の医療会社。多臓器不全を治療するために炎症を調節する血液浄化技術プラットフォ―ムを使用して免疫療法を行う。欧州連合で、体外サイトカインフィルタ「CytoSorb」デバイスを販売する。また血液浄化システム「HomoDefend」と血液から有毒な薬を取り除く「DrugSorb」を開発する。   CytoSorbents Corp is a immunotherapy company. The Company uses blood purification to modulate inflammation with the goal of preventing or treating multiple organ failure in life-threatening illnesses and cardiac surgery.
本社所在地 7 Deer Park Drive Suite K Monmouth Junction NJ 08852 USA
設立年月日 37347
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 84人
url www.cytosorbents.com
nasdaq_url https://www.nasdaq.com/symbol/ctso
EBITDA EBITDA(百万ドル) -13.01103
終値(lastsale) 11.61
時価総額(marketcap) 365244133.23
時価総額 時価総額(百万ドル) 360.83980
売上高 売上高(百万ドル) 19.15110
企業価値(EV) 企業価値(EV)(百万ドル) 345.45086
当期純利益 当期純利益(百万ドル) -14.00454
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cytosorbents Corp revenues increased 60% to $10.7M. Net loss increased from $3.3M to $8.8M. Revenues reflect CytoSorb sales increase of 71% to $9.6M Other sales increase from $14K to $88K. Higher net loss reflects General and administrative -other increase of 49% to $7.8M (expense) Stock-based Compensation in SGA increase from $876K to $2.5M (expense).



   Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2019 Results - Earnings Call Transcript  2019-05-07
Cytosorbents Corporation (CTSO) Q1 2019 Earnings Conference Call May 7, 2019 4:45 p.m. ET Company Participants Jeremy Feffer - IR, LifeSci Advisors Phillip Chan - CEO and President Vincent Capponi - COO Kathleen Bloch - CFO Eric Mortensen - Chief Medical Officer Christian S…

 関連キーワード  (先端医療機器_テクノロジ― 米国株 シトソ―ベンツ CTSO Cytosorbents Corporation)


 twitter  (公式ツイッターやCEOツイッターなど)